Uterine serous carcinomas frequently metastasize to the fallopian tube and can mimic serous tubal intraepithelial carcinoma

American Journal of Surgical Pathology

Volumn 41, Issue 2, 2017, Pages 161-170

  Kommoss, Friedrich ^a   Faruqi, Asma ^b   Gilks, C Blake ^a   Leen, Sarah Lamshang ^c   Singh, Naveena ^c   Wilkinson, Nafisa ^d   McCluggage, W Glenn ^e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Barts NHS Trust ^*  (United Kingdom)

^c BARTS HEALTH NHS TRUST   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

Fallopian tube, serous tubal intraepithelial carcinoma; Independent primary; Metastasis; Uterine serous carcinoma

Indexed keywords

TUMOR MARKER;

ADULT; AGED; CARCINOMA IN SITU; CYSTADENOCARCINOMA, SEROUS; DIFFERENTIAL DIAGNOSIS; FALLOPIAN TUBE; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PATHOLOGY; SECONDARY; UTERINE NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA IN SITU; CYSTADENOCARCINOMA, SEROUS; DIAGNOSIS, DIFFERENTIAL; FALLOPIAN TUBE NEOPLASMS; FALLOPIAN TUBES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; UTERINE NEOPLASMS;

EID: 84992317626     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000757     Document Type: Article

References (29)

1. Ellenson LH, Ronnett BM, Soslow RA, et al. Endometrial Carcinoma. In: Blaustein A, Kurman RJ, eds. Blaustein's pathology of the female genital tract. 6th ed. New York, NY: Springer; 2011: 393-451.
2. Dunton CJ, Balsara G, McFarland M, et al. Uterine papillary serous carcinoma: a review. Obstet Gynecol Surv. 1991;46: 97-102.
3. Darvishian F, Hummer AJ, Thaler HT, et al. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. Am J Surg Pathol. 2004;28: 1568-1578.
4. Ambros RA, ShermanME, Zahn CM, et al. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol. 1995;26: 1260-1267.
5. McConechy MK, Ding J, Cheang MC, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol. 2012;228: 20-30.
6. Sherman ME, Bitterman P, Rosenshein NB, et al. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol. 1992;16: 600-610.
7. Wheeler DT, Bell KA, Kurman RJ, et al. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol. 2000;24: 797-806.
8. Singh N, Gilks CB, Hirshowitz L, et al. Adopting a uniform approach to site assignment in tubo-ovarian high-grade serous carcinoma: the time has come. Int J Gynecol Pathol. 2016;35: 230-237.
9. Gilks CB, Irving J, Köbel M, et al. Incidental nonuterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas. Am J Surg Pathol. 2015;39: 357-364.
10. Singh N, Gilks CB, Wilkinson N, et al. The secondary Mullerian system, field effect, BRCA, and tubal fimbria: our evolving understanding of the origin of tubo-ovarian high-grade serous carcinoma and why assignment of primary site matters. Pathology. 2015;47: 423-431.
11. Singh N, Gilks CB, Hirschowitz L, et al. Primary site assignment in tubo-ovarian high-grade serous carcinoma: Consensus statement on unifying practice worldwide. Gynecol Oncol. 2016;141: 195-198.
12. Singh N, Gilks CB, Wilkinson N, et al. Assessment of a new system for primary site assignment in high-grade serous carcinoma of the fallopian tube, ovary, and peritoneum. Histopathology. 2015;67: 331-337.
13. Morrison JC, Blanco LZ Jr, Vang R, et al. Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series. Am J Surg Pathol. 2015;39: 442-453.
14. Rabban JT, Vohra P, Zaloudek CJ. Nongynecologic metastases to fallopian tube mucosa: a potential mimic of tubal high-grade serous carcinoma and benign tubal mucinous metaplasia or nonmucinous hyperplasia. Am J Surg Pathol. 2015;39: 35-51.
15. Mingels MJ, Van Ham MA, De Kievit IM, et al. Mullerian precursor lesions in serous ovarian cancer patients: using the SEEFim and SEE-End protocol. Mod Pathol. 2014;27: 1002-1013.
16. Tolcher MC, Swisher EM, Medeiros F, et al. Characterization of precursor lesions in the endometrium and fallopian tube epithelium of early-stage uterine serous carcinoma. Int J Gynecol Pathol. 2015;34: 57-64.
17. Stewart CJ, Armstrong M, Brennan BA, et al. Coexisting serous carcinoma of the endometrium and the fallopian tube. Int J Gynecol Pathol. 2010;29: 278-281.
18. Jarboe EA, Miron A, Carlson JW, et al. Coexisting intraepithelial serous carcinomas of the endometrium and fallopian tube: frequency and potential significance. Int J Gynecol Pathol. 2009; 28: 308-315.
19. Jia L, Yuan Z, Wang Y, et al. Primary sources of pelvic serous cancer in patients with endometrial intraepithelial carcinoma. Mod Pathol. 2015;28: 118-127.
20. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30: 230-236.
21. Lee Y, Medeiros F, Kindelberger D, et al. Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol. 2006;13: 1-7.
22. Köbel M, Piskorz AMM, Lee S, et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol: Clin Res. 2016. [Epub ahead of print]
23. Pennington KP, Walsh T, Lee M, et al. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. Cancer. 2013;119: 332-338.
24. Goldstein NS, Uzieblo A. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol. 2002;117: 541-545.
25. Al-Hussaini M, Stockman A, Foster H, et al. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2004;44: 109-115.
26. Hedley C, Sriraksa R, Showeil R, et al. The frequency and significance of WT-1 expression in serous endometrial carcinoma. Hum Pathol. 2014;45: 1879-1884.
27. Hirschowitz L, Ganesan R, McCluggage WG. WT1, p53 and hormone receptor expression in uterine serous carcinoma. Histopathology. 2009;55: 478-482.
28. Snyder MJ, Bentley R, Robboy SJ. Transtubal spread of serous adenocarcinoma of the endometrium: an underrecognized mechanism of metastasis. Int J Gynecol Pathol. 2006;25: 155-160.
29. Bijron JG, Seldenrijk CA, Zweemer RP, et al. Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis. Am J Surg Pathol. 2013;37: 1123-1130.